
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics is poised for success with their expanded pipeline addressing underserved neuropsychiatric disorders and neurodegenerative diseases. With promising data from multiple clinical trials and a strong financial position, the company has the potential for significant growth in the future. The company's management team has demonstrated their ability to successfully advance their products through the development process, giving investors confidence in the company's capabilities. This, combined with the potential for multiple upcoming valuation swing events, leads to a positive outlook for Neumora Therapeutics and its potential for long-term success.
Bears say
Neumora Therapeutics is a clinical-stage biopharmaceutical company with a pipeline of seven clinical and preclinical programs targeting neuropsychiatric disorders and neurodegenerative diseases. However, despite the positive outlook on their lead program NMRA-898 for schizophrenia, their other pipeline programs are still in early stages and face a lot of competition. Additionally, NMRA's financials may be impacted by the need for further clinical studies and potential safety concerns in the future. Overall, the stock's outlook may be negative due to the uncertainty and risk associated with their pipeline and financials.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares